Inoviq Ltd (AU:IIQ) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inoviq Ltd has announced a breakthrough in ovarian cancer testing, with its EXO-OC blood test achieving over 94% accuracy in independent patient validation. This promising development could revolutionize early-stage ovarian cancer detection, crucially improving patient outcomes and survival rates. The company plans to optimize the test for commercial use and further clinical validation.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.